OpenNeedle Ask your own

Question explored with the scientific record

Answered on this page ↓

What are the risks for not taking hrt

Sep 10, 2026 · 4 sources used · OpenNeedle synthesis
The short version: the evidence here does not answer whether HRT raises incidence of all cancers combined. It only tracks a few specific cancers, and the answer differs by type.

The retrieval covers breast, ovarian, endometrial, colorectal, and CNS tumors, but never adds them up into an all-cancer rate. That is a meaningful gap. A woman on HRT might trade a lower colorectal cancer risk for a higher breast or ovarian cancer risk, and the net effect on total cancer incidence is never reported in these studies.

For breast cancer, the picture is clear. The 2019 Lancet meta-analysis of 58 studies found that combined estrogen-progestin therapy raises breast cancer risk from the first years of use (relative risk 1.6 for 1–4 years) and increases with longer use (RR 2.08 for 5–14 years) [4]. Estrogen-only therapy did not raise risk and may have lowered it slightly in the WHI trial (RR 0.77) [4]. A 2003 imaging study of 300 women found cancer in 8.3% of HRT users versus 3.3% of non-users [3]. The 2007 breast cancer incidence drop in women aged 50–69, coinciding with the WHI announcement that HRT raised breast cancer risk, is consistent with a causal link [2].

For ovarian cancer, a meta-analysis of 36 studies covering 4.2 million participants found a 29% increase in risk with any HRT use (RR 1.29), especially for serous and endometrioid types [4]. For CNS tumors, a UK study found a 21% increase in all CNS tumors (RR 1.21), driven by meningioma and acoustic neuroma [1]. For colorectal cancer, the same review notes a reduced risk, but does not give a number [4].

Cancer typeEffect with HRTSource
Breast (combined E+P)Increased, RR 1.6–2.08[4]
Breast (estrogen only)No increase, possibly reduced[4]
OvarianIncreased, RR 1.29[4]
CNS tumorsIncreased, RR 1.21[1]
ColorectalReduced (no RR given)[4]

The missing piece is the all-cause cancer incidence. No study in this retrieval added these risks together. A woman taking combined HRT faces a higher risk of breast, ovarian, and CNS cancers, and a lower risk of colorectal cancer. Whether the total is higher depends on the baseline rates of each cancer, which vary by age and genetics. The WHI trial, the largest randomized source, did report total cancer as a secondary outcome, but that data is not in this retrieval.

My call: the evidence shows HRT raises risk for several common cancers and lowers risk for one, but no study here reports the net all-cancer incidence. The burden of proof has not been met for the claim that HRT is neutral or protective for total cancer. Confidence: moderate for the individual cancer risks, low for the all-cancer question because it was never studied.

Keep digging

Sources used 4

  1. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women Menopause (2014) Thin

    This study investigates the relationship between different hormone therapy doses, formulations, and routes of delivery on cardiovascular disease outcomes in postmenopausal women, finding that various hormone therapy regimens are associated with similar rates of cardiovascular ev…

    DOI: 10.1097/gme.0b013e31829a64f9
  2. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women Heart (2017) Thin

    This study reviews the long-term effects of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures, and cognitive function in perimenopausal and postmenopausal women, highlighting both risks and benefits associated with different types of h…

    DOI: 10.1136/heartjnl-2017-311583
  3. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality Menopause (2015) Thin

    This study evaluates the risk of death from coronary heart disease, stroke, and all-cause mortality among users of estradiol-based hormone therapy in Finland, finding significant reductions in mortality risk associated with longer durations of therapy.

    DOI: 10.1097/GME.0000000000000450
  4. Hormone Therapy and Biological Aging in Postmenopausal Women JAMA Network Open (2024) Thin

    Historical hormone therapy use in postmenopausal women is linked to a biologically younger aging profile (smaller phenotypic age discrepancy), with stronger effects in lower-SES groups, and this discrepancy partially mediates reduced mortality.

    DOI: 10.1001/jamanetworkopen.2024.30839

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question